1
|
Sathibabu Uddandrao VV, Brahmanaidu P,
Ravindarnaik R, Suresh P, Vadivukkarasi S and Saravanan G:
Restorative potentiality of S-allylcysteine against diabetic
nephropathy through attenuation of oxidative stress and
inflammation in streptozotocin-nicotinamide-induced diabetic rats.
Eur J Nutr. July 30–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
2
|
Wagnew F, Eshetie S, Kibret GD, Zegeye A,
Dessie G, Mulugeta H and Alemu A: Diabetic nephropathy and
hypertension in diabetes patients of sub-Saharan countries: A
systematic review and meta-analysis. BMC Res Notes. 11:5652018.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Mafi A, Aghadavod E, Mirhosseini N, Mobini
M and Asemi Z: The effects of expression of different microRNAs on
insulin secretion and diabetic nephropathy progression. J Cell
Physiol. 234:42–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
4
|
Song X, Gong M, Chen Y, Liu H and Zhang J:
Nine hub genes as the potential indicator for the clinical outcome
of diabetic nephropathy. J Cell Physiol. 234:1461–1468. 2019.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Liu P, Peng L, Zhang H, Tang PM, Zhao T,
Yan M, Zhao H, Huang X, Lan H and Li P: Tangshen formula attenuates
diabetic nephropathy by promoting ABCA1-mediated renal cholesterol
efflux in db/db Mice. Front Physiol. 9:3432018. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wu T, Li Q, Wu T and Liu HY:
Identification of biological targets of therapeutic intervention
for diabetic nephropathy with bioinformatics approach. Exp Clin
Endocrinol Diabetes. 122:587–591. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Ziyadeh FN and Wolf G: Pathogenesis of the
podocytopathy and proteinuria in diabetic glomerulopathy. Curr
Diabetes Rev. 4:39–45. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Wu J, Liu J, Ding Y, Zhu M, Lu K, Zhou J,
Xie X, Xu Y, Shen X, Chen Y, et al: MiR-455-3p suppresses renal
fibrosis through repression of ROCK2 expression in diabetic
nephropathy. Biochem Biophys Res Commun. 503:977–983. 2018.
View Article : Google Scholar : PubMed/NCBI
|
9
|
He F, Peng F, Xia X, Zhao C, Luo Q, Guan
W, Li Z, Yu X and Huang F: MiR-135a promotes renal fibrosis in
diabetic nephropathy by regulating TRPC1. Diabetologia.
57:1726–1736. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Putta S, Lanting L, Sun G, Lawson G, Kato
M and Natarajan R: Inhibiting MicroRNA-192 Ameliorates renal
fibrosis in diabetic nephropathy. J Am Soc Nephrol. 23:458–469.
2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Chen Y, Qiao F, Zhao Y, Wang Y and Liu G:
HMGB1 is activated in type 2 diabetes mellitus patients and in
mesangial cells in response to high glucose. Int J Clin Exp Pathol.
8:6683–6691. 2015.PubMed/NCBI
|
12
|
Seo E, Kang H, Oh YS and Jun HS: Psoralea
corylifolia L. Seed extract attenuates diabetic nephropathy by
inhibiting renal fibrosis and apoptosis in streptozotocin-induced
diabetic mice. Nutrients. 9(pii): E8282017. View Article : Google Scholar : PubMed/NCBI
|
13
|
Braga Gomes K, Fontana Rodrigues K and
Fernandes AP: The role of transforming growth factor-beta in
diabetic nephropathy. Int J Med Genet. 2014:1–6. 2014. View Article : Google Scholar
|
14
|
Hills CE and Squires PE: The role of TGF-β
and epithelial-to mesenchymal transition in diabetic nephropathy.
Cytokine Growth Factor Rev. 22:131–139. 2011.PubMed/NCBI
|
15
|
Cheng DW, Jiang Y, Shalev A, Kowluru R,
Crook ED and Singh LP: An analysis of high glucose and
glucosamine-induced gene expression and oxidative stress in renal
mesangial cells. Arch Physiol Biochem. 112:189–218. 2006.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Chen Y, Teng L, Liu W, Cao Y, Ding D, Wang
W, Chen H, Li C and An R: Identification of biological targets of
therapeutic intervention for clear cell renal cell carcinoma based
on bioinformatics approach. Cancer Cell Int. 16:162016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Tang Y, Zhang Z, Tang Y, Chen X and Zhou
J: Identification of potential target genes in pancreatic ductal
adenocarcinoma by bioinformatics analysis. Oncol Lett.
16:2453–2461. 2018.PubMed/NCBI
|
18
|
Kanehisa M, Goto S, Sato Y, Furumichi M
and Tanabe M: KEGG for integration and interpretation of
large-scale molecular data sets. Nucleic Acids Res 40 (Database
Issue). D109–D114. 2012. View Article : Google Scholar
|
19
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
20
|
Wishart DS, Feunang YD, Guo AC, Lo EJ,
Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, et al:
DrugBank 5.0: A major update to the DrugBank database for 2018.
Nucleic Acids Res. 46:D1074–D1082. 2018. View Article : Google Scholar : PubMed/NCBI
|
21
|
Hsin KY, Matsuoka Y, Asai Y, Kamiyoshi K,
Watanabe T, Kawaoka Y and Kitano H: SystemsDock: A web server for
network pharmacology-based prediction and analysis. Nucleic Acids
Res. 44:W507–W513. 2016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Hsin KY, Ghosh S and Kitano H: Combining
machine learning systems and multiple docking simulation packages
to improve docking prediction reliability for network pharmacology.
PLoS One. 8:e839222013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Ma J, Zhang L, Hao J, Li N, Tang J and Hao
L: Up-regulation of microRNA-93 inhibits TGF-β1-induced EMT and
renal fibrogenesis by down-regulation of Orai1. J Pharmacol Sci.
136:218–227. 2018. View Article : Google Scholar : PubMed/NCBI
|
24
|
Deshpande S, Abdollahi M, Wang M, Lanting
L, Kato M and Natarajan R: Reduced autophagy by a microRNA-mediated
signaling cascade in diabetes-induced renal glomerular hypertrophy.
Sci Rep. 8:69542018. View Article : Google Scholar : PubMed/NCBI
|
25
|
Song KH, Park J, Park JH, Natarajan R and
Ha H: Fractalkine and its receptor mediate extracellular matrix
accumulation in diabetic nephropathy in mice. Diabetologia.
56:1661–1669. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Kanwar YS, Sun L, Xie P, Liu FY and Chen
S: A glimpse of various pathogenetic mechanisms of diabetic
nephropathy. Annu Rev Pathol. 6:395–423. 2011. View Article : Google Scholar : PubMed/NCBI
|
27
|
Reidy K, Kang HM, Hostetter T and Susztak
K: Molecular mechanisms of diabetic kidney disease. J Clin Invest.
124:2333–2340. 2014. View
Article : Google Scholar : PubMed/NCBI
|
28
|
Meng XM, Nikolic-Paterson DJ and Lan HY:
TGF-β: The master regulator of fibrosis. Nat Rev Nephrol.
12:325–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
29
|
Lim AK and Tesch GH: Inflammation in
diabetic nephropathy. Mediators Inflamm. 2012:1461542012.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Lan HY: Transforming growth factor-β/Smad
signalling in diabetic nephropathy. Clin Exp Pharmacol Physiol.
39:731–738. 2012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Xu L, Shen P, Bi Y, Chen J, Xiao Z, Zhang
X and Wang Z: Danshen injection ameliorates STZ-induced diabetic
nephropathy in association with suppression of oxidative stress,
pro-inflammatory factors and fibrosis. Int Immunopharmacol.
38:385–394. 2016. View Article : Google Scholar : PubMed/NCBI
|
32
|
Jochum W, Passegué E and Wagner EF: AP-1
in mouse development and tumorigenesis. Oncogene. 20:2401–2412.
2001. View Article : Google Scholar : PubMed/NCBI
|
33
|
Weigert C, Sauer U, Brodbeck K, Pfeiffer
A, Häring HU and Schleicher ED: AP-1 proteins mediate
hyperglycemia-induced activation of the human TGF-beta1 promoter in
mesangial cells. J Am Soc Nephrol. 11:2007–2016. 2000.PubMed/NCBI
|
34
|
Gao P, Wei Y, Zhang Z, Zeng W, Sun D, Liu
D, Hou B, Zhang C, Zhang N, Li H and Li L: Synergistic effects of
c-Jun and SP1 in the promotion of TGFβ1-mediated diabetic
nephropathy progression. Exp Mol Pathol. 100:441–450. 2016.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Wang X, Yao B, Wang Y, Fan X, Wang S, Niu
A, Yang H, Fogo A, Zhang MZ and Harris RC: Macrophage
Cyclooxygenase-2 protects against development of diabetic
nephropathy. Diabetes. 66:494–504. 2017. View Article : Google Scholar : PubMed/NCBI
|
36
|
Watanabe Y, Yamaguchi T, Ishihara N,
Nakamura S, Tanaka S, Oka R, Imamura H, Sato Y, Ban N, Kawana H, et
al: 7-Ketocholesterol induces ROS-mediated mRNA expression of
12-lipoxygenase, cyclooxygenase-2 and pro-inflammatory cytokines in
human mesangial cells: Potential role in diabetic nephropathy.
Prostaglandins Other Lipid Mediat. 134:16–23. 2018. View Article : Google Scholar : PubMed/NCBI
|
37
|
Cheng HF, Wang CJ, Moeckel GW, Zhang MZ,
McKanna JA and Harris RC: Cyclooxygenase-2 inhibitor blocks
expression of mediators of renal injury in a model of diabetes and
hypertension1. Kidney Int. 62:929–939. 2002. View Article : Google Scholar : PubMed/NCBI
|
38
|
Cheng H, Fan X, Moeckel GW and Harris RC:
Podocyte COX-2 exacerbates diabetic nephropathy by increasing
podocyte (pro)renin receptor expression. J Am Soc Nephrol.
22:1240–1251. 2011. View Article : Google Scholar : PubMed/NCBI
|
39
|
Ma X, Lu C, Lv C and Wang Q: The
expression of miR-192 and its significance in diabetic nephropathy
patients with different urine albumin creatinine ratio. J Diabetes
Res. 2016:67894022016. View Article : Google Scholar : PubMed/NCBI
|
40
|
Tian RQ, Wang XH, Hou LJ, Jia WH, Yang Q,
Li YX, Liu M, Li X and Tang H: MicroRNA-372 is down-regulated and
targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human
cervical cancer, which may contribute to tumorigene. J Biol Chem.
286:25556–25563. 2011. View Article : Google Scholar : PubMed/NCBI
|
41
|
Saurus P, Kuusela S, Dumont V, Lehtonen E,
Fogarty CL, Lassenius MI, Forsblom C, Lehto M, Saleem MA, Groop PH
and Lehtonen S: Cyclin-dependent kinase 2 protects podocytes from
apoptosis. Sci Rep. 6:216642016. View Article : Google Scholar : PubMed/NCBI
|
42
|
Huang K, Huang J, Chen C, Hao J, Wang S,
Huang J, Liu P and Huang H: AP-1 regulates sphingosine kinase 1
expression in a positive feedback manner in glomerular mesangial
cells exposed to high glucose. Cell Signal. 26:629–638. 2014.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Chen S, Mukherjee S, Chakraborty C and
Chakrabarti S: High glucose-induced, endothelin-dependent
fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J
Physiol Cell Physiol. 284:C263–C272. 2003. View Article : Google Scholar : PubMed/NCBI
|
44
|
Haneda M, Koya D, Isono M and Kikkawa R:
Overview of glucose signaling in mesangial cells in diabetic
nephropathy. J Am Soc Nephrol. 14:1374–1382. 2003. View Article : Google Scholar : PubMed/NCBI
|
45
|
Cao AL, Wang L, Chen X, Wang YM, Guo HJ,
Chu S, Liu C, Zhang XM and Peng W: Ursodeoxycholic acid and
4-phenylbutyrate prevent endoplasmic reticulum stress-induced
podocyte apoptosis in diabetic nephropathy. Lab Invest. 96:610–622.
2016. View Article : Google Scholar : PubMed/NCBI
|
46
|
Chen Y, Gui D, Chen J, He D, Luo Y and
Wang N: Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside
IV is associated with the inhibition of endoplasmic reticulum
stress-induced podocyte apoptosis in diabetic rats. Cell Physiol
Biochem. 33:1975–1987. 2014. View Article : Google Scholar : PubMed/NCBI
|
47
|
Lindenmeyer MT, Rastaldi MP, Ikehata M,
Neusser MA, Kretzler M, Cohen CD and Schlöndorff D: Proteinuria and
hyperglycemia induce endoplasmic reticulum stress. J Am Soc
Nephrol. 19:2225–2236. 2008. View Article : Google Scholar : PubMed/NCBI
|
48
|
Chen J, Hou XF, Wang G, Zhong QX, Liu Y,
Qiu HH, Yang N, Gu JF, Wang CF, Zhang L, et al: Terpene glycoside
component from Moutan Cortex ameliorates diabetic nephropathy by
regulating endoplasmic reticulum stress-related inflammatory
responses. J Ethnopharmacol. 193:433–444. 2016. View Article : Google Scholar : PubMed/NCBI
|
49
|
Eletto D, Dersh D and Argon Y: GRP94 in ER
quality control and stress responses. Semin Cell Dev Biol.
21:479–485. 2010. View Article : Google Scholar : PubMed/NCBI
|
50
|
Huang M and Prendergast GC: RhoB in cancer
suppression. Histol Histopathol. 21:213–218. 2006.PubMed/NCBI
|
51
|
Bravo-Nuevo A, Sugimoto H, Iyer S, Fallon
Z, Lucas JM, Kazerounian S, Prendergast GC, Kalluri R, Shapiro NI
and Benjamin LE: RhoB loss prevents streptozotocin-induced diabetes
and ameliorates diabetic complications in mice. Am J Pathol.
178:245–252. 2011. View Article : Google Scholar : PubMed/NCBI
|
52
|
Mehta G, Ferreira VP, Skerka C, Zipfel PF
and Banda NK: New insights into disease-specific absence of
complement factor H related protein C in mouse models of
spontaneous autoimmune diseases. Mol Immunol. 62:235–248. 2014.
View Article : Google Scholar : PubMed/NCBI
|
53
|
Bonomo JA, Palmer ND, Hicks PJ, Lea JP,
Okusa MD, Langefeld CD, Bowden DW and Freedman BI: Complement
factor H gene associations with end-stage kidney disease in African
Americans. Nephrol Dial Transplant. 29:1409–1414. 2014. View Article : Google Scholar : PubMed/NCBI
|
54
|
Mallipattu SK, Estrada CC and He JC: The
critical role of Krüppel-like factors in kidney disease. Am J
Physiol Renal Physiol. 312:F259–F265. 2017. View Article : Google Scholar : PubMed/NCBI
|
55
|
Guo Y, Pace J, Li Z, Ma'ayan A, Wang Z,
Revelo MP, Chen E, Gu X, Attalah A, Yang Y, Estrada C, et al:
Podocyte-specific induction of Krüppel-like factor 15 restores
differentiation markers and attenuates kidney injury in proteinuric
kidney disease. J Am Soc Nephrol. 29:2529–2545. 2018. View Article : Google Scholar : PubMed/NCBI
|